Veracyte, Inc. (NASDAQ:VCYT) Shares Bought by Gotham Asset Management LLC

Gotham Asset Management LLC lifted its position in shares of Veracyte, Inc. (NASDAQ:VCYT) by 21.5% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 20,057 shares of the biotechnology company’s stock after acquiring an additional 3,549 shares during the period. Gotham Asset Management LLC’s holdings in Veracyte were worth $794,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in the company. Jones Financial Companies Lllp boosted its holdings in Veracyte by 49.7% in the fourth quarter. Jones Financial Companies Lllp now owns 714 shares of the biotechnology company’s stock worth $28,000 after purchasing an additional 237 shares during the period. Arizona State Retirement System lifted its position in shares of Veracyte by 1.2% in the 4th quarter. Arizona State Retirement System now owns 22,276 shares of the biotechnology company’s stock worth $882,000 after buying an additional 264 shares during the last quarter. Synovus Financial Corp boosted its holdings in shares of Veracyte by 1.2% in the 4th quarter. Synovus Financial Corp now owns 23,132 shares of the biotechnology company’s stock valued at $916,000 after buying an additional 267 shares during the period. HighTower Advisors LLC grew its position in shares of Veracyte by 1.9% during the 4th quarter. HighTower Advisors LLC now owns 16,630 shares of the biotechnology company’s stock valued at $659,000 after buying an additional 305 shares during the last quarter. Finally, Principal Securities Inc. grew its position in shares of Veracyte by 34.1% during the 4th quarter. Principal Securities Inc. now owns 1,909 shares of the biotechnology company’s stock valued at $76,000 after buying an additional 485 shares during the last quarter.

Veracyte Stock Performance

NASDAQ:VCYT opened at $29.20 on Monday. The stock has a market cap of $2.29 billion, a price-to-earnings ratio of -194.67 and a beta of 2.14. Veracyte, Inc. has a 1 year low of $19.73 and a 1 year high of $47.32. The business has a fifty day moving average of $30.79 and a 200-day moving average of $36.96.

Veracyte (NASDAQ:VCYT) last posted its quarterly earnings data on Monday, February 24th. The biotechnology company reported $0.36 earnings per share for the quarter, topping the consensus estimate of $0.29 by $0.07. The business had revenue of $118.63 million during the quarter, compared to the consensus estimate of $110.73 million. Veracyte had a negative net margin of 2.18% and a positive return on equity of 3.02%. During the same quarter in the prior year, the company posted ($0.39) earnings per share. On average, equities research analysts predict that Veracyte, Inc. will post 0.68 EPS for the current year.

Analyst Ratings Changes

A number of equities analysts have issued reports on VCYT shares. Needham & Company LLC cut their target price on shares of Veracyte from $51.00 to $41.00 and set a “buy” rating on the stock in a report on Thursday, May 8th. Stephens reissued an “overweight” rating and issued a $45.00 price target on shares of Veracyte in a report on Wednesday, March 26th. UBS Group lowered their price objective on Veracyte from $49.00 to $42.00 and set a “buy” rating for the company in a research note on Thursday, May 8th. Craig Hallum assumed coverage on Veracyte in a research report on Thursday, March 20th. They issued a “buy” rating and a $45.00 target price on the stock. Finally, Guggenheim reduced their price target on shares of Veracyte from $45.00 to $37.00 and set a “buy” rating for the company in a report on Wednesday, April 9th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat, Veracyte presently has a consensus rating of “Moderate Buy” and a consensus price target of $40.90.

Veracyte Company Profile

Veracyte, Inc engages in the research, development and commercialization of diagnostic products. The firm’s portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H.